Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
Abnormal uterine bleeding: When can you forgo biopsy?
- Author:
- Sharon Worcester
NASHVILLE, TENN. – Recurrent bleeding and endometrial thickening can help guide the initial approach to evaluating...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Espey_Eve_NEW MEXICO_web.jpg)
Bilateral salpingectomy gains favor for sterilization
- Author:
- Sharon Worcester
NASHVILLE, TENN. – Bilateral salpingectomy is gaining favor in both vaginal and cesarean delivery settings.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/fish_web.jpg)
The FDA has revised its guidance on fish consumption
- Author:
- Sharon Worcester
The FDA has revised its 2017 guidance to promote healthy intake and safer choices for children and women who are pregnant, nursing, or might...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Chiuve_Stephanie_CHICAGO_web.jpg)
Claims data suggest endometriosis ups risk of chronic opioid use
- Author:
- Sharon Worcester
Women with endometriosis had a nearly 300% higher rate of chronic opioid use, compared with those without endometriosis, according to an analysis...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/141086_Espey_Eve_web.jpg)
Dr. Eve Espey: Some good news in her 2019 contraceptive update
- Author:
- Sharon Worcester
NASHVILLE, TENN. – Unplanned pregnancy and abortion rates are down, and the future...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/141133_simonsen_saraE_web.jpg)
LARC prolongs interpregnancy intervals but doesn’t cut preterm birth risk
- Author:
- Sharon Worcester
NASHVILLE, TENN. – LARC use reduces short interpregnancy intervals, but does not appear to reduce the risk of...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/RenzelliCain_Roberta_WV_web.jpg)
Survey: Patient-provider communication regarding dyspareunia disappoints
- Author:
- Sharon Worcester
NASHVILLE, TENN. – Communication between patients and HCPs about endometriosis-related dyspareunia is suboptimal, according to results of an...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/krop_ian_boston_web.jpg)
APHINITY trial: Biomarker analysis IDs predictive, prognostic factors
- Author:
- Sharon Worcester
CHICAGO – Higher levels of several immune markers confer better prognosis in HER2-positive breast cancer patients treated with trastuzumab and...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/140974_OLeary_Ben_web.jpg)
PALOMA-3 biomarker analysis: Liquid biopsy could ID progression risk
- Author:
- Sharon Worcester
TP53 mutation, FGFR1 amplification, and tumor purity in plasma each predict early progression on palbociclib and/or fulvestrant in patients with...
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
TAILORx: Clinical data add value to recurrence score
- Author:
- Sharon Worcester
CHICAGO – Clinical risk stratification adds prognostic value to the 21-gene recurrence score for guiding treatment selection in patients with...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/bergh_jonas_sweden_web.jpg)
PREDIX HER2 trial: Similar efficacy, less toxicity with T-DM1 for HER2+, HR+ breast cancer
- Author:
- Sharon Worcester
T-DM1 had similar efficacy and less toxicity vs. standard chemotherapy for patients with HER2- and HR-positive breast cancers in the phase 2...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/hurvitz_sara_CALIF_web.jpg)
KRISTINE: Three-year data help forge path to T-DM1-based deescalation in HER2+ BC
- Author:
- Sharon Worcester
CHICAGO – T-DM1 plus pertuzumab reduced toxicity in patients with HER2-positive stage I-III breast cancer in the KRISTINE study, but led to lower...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/capture_105.jpg)
Nearly two-thirds of gynecologic oncology respondents experienced sexual harassment
- Author:
- Sharon Worcester
CHICAGO – A survey suggests sexual harassment remains rampant in the gynecologic oncology field, with both women and...
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
FDA launches call center project to streamline Expanded Access request process
- Author:
- Sharon Worcester
CHICAGO – Project Facilitate is a pilot call center project designed to create a single point of contact with FDA oncology staff who can guide...
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/capture_98.jpg)
ENZAMET trial: Early enzalutamide delays progression, improves survival in mHSPC
- Author:
- Sharon Worcester
CHICAGO –Enzalutamide with standard first-line testosterone suppression delays progression and improves survival in...